Merck KGgA venture arm bets on ‘next generation’ cancer therapeutics player

M Ventures, the strategic, corporate venture capital arm of Merck KGgA, continues to fund iOmx Therapeutics AG, a company developing cancer therapeutics based on next generation immune checkpoint targets.